DSM Anti-Infectives enters into partnership with Indian company Arch Pharmalabs Ltd.
DSM Anti-Infectives, a business group of Royal DSM N.V., the global life sciences and materials sciences company headquartered in the Netherlands, and Mumbai (IN) based Arch Pharmalabs Ltd., a pharmaceutical company manufacturing active pharmaceutical ingredients (APIs), have signed a partnership agreement.
In the partnership DSM Anti-Infectives will contribute its innovative fermentative technologies and market access to the partnership, whereas Arch will utilize its asset base in India and its competences in chemical conversion ”This will accelerate the development of new products for DSM Anti-Infectives” commented Gerard de Reuver, Business Group Director DSM Anti-Infectives.
As announced in June 2007, DSM Anti-Infectives is currently rationalizing its portfolio and actively looking for partnerships. A part of the current portfolio (such as clavulanic acid) will be divested and new products will be developed.
DSM Anti-Infectives is the world’s leading supplier of active pharmaceutical ingredients such as amoxicillin, ampicillin, cephalexin and cefadroxil, the worlds most widely used broad spectrum antibiotics for combating bacterial infections. Its product portfolio also includes clavulanic acid, nystatin, penicillin, penicillin intermediates (6-APA and 7-ADCA), industrial enzymes and side chains. The company is headquartered in Delft, the Netherlands, and has a global presence with manufacturing facilities in Europe, Africa, China and India and sales offices across the globe. More information can be found on http://www.dsm.com/en_US/html/dai/daihomepage.htm.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.